A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia

Leukemia Research

Volumn 27, Issue 1, 2003, Pages 35-44

  Cooper, Brenda W ^a   Donaher, Erin ^a   Lazarus, Hillard M ^a   Green, Sylvan B ^a   Gosky, David M ^a   Rosenthal, Nancy S ^a   Berger, Sosamma J ^a   Li, Xiaolin ^a   Ingalls, Stephen T ^a   Hoppel, Charles L ^a   Gerson, Stanton L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute leukemia; Sequential topoisomerase I and II inhibitors

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DOSE CALCULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; INFECTIOUS COMPLICATION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REMISSION; STOMATITIS;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BONE MARROW; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; GASTROINTESTINAL DISEASES; HEPATITIS, TOXIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TOPOTECAN;

EID: 0037212016     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00079-6     Document Type: Article

References (56)

1. Rowinsky E.K., Adjei A., Donehower R.C., Gore S.D., Jones R.J., Burke P.J.et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol. 2:1994;2193-2203.
2. Kantarjian H.M., Beran M., Ellis A.et al. Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood. 81:1993;1146-1151.
3. Beran M., Kantarjian H., Keating M.et al. Results of topotecan and high dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 90:1997;2593a.
4. Crump M., Lipton J., Hedley D., Sutton D., Shepherd F., Minden M.et al. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia. A National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 13:1999;343-347.
5. Seiter K., Feldman E.J., Halick D., Traganos F., Darzynkiewicz A., Lake D.et al. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J. Clin. Oncol. 15:1997;44-51.
6. Hertzberg R.P., Carang M.J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme DNA complex. Biochemistry. 28:1989;4629-4638.
7. Bjornsti M.A., Benedetti P., Viglianti G.A. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the anti-tumor drug camptothecin. Cancer Res. 49:1989;6318-6323.
8. Madden K.R., Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res. 52:1992;525-532.
9. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M.et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer. 50:1992;604-610.
10. Bertrand R., O'Connor P.M., Kerrigan D., Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer. 28A:1992;743-748.
11. Kim R., Hirabayashi N., Nishiyama M., Jinushi K., Toge T., Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer. 50:1992;760-766.
12. Eder J.P., Chan V., Wong J., Wong Y.W., Ara G., Northey D.et al. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother. Pharmacol. 42:1998;327-335.
13. Whitacre C.M., Zborowska E., Gordon N.H., Mackay W., Berger N.A. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule dependent process. Cancer Res. 57:1997;1425-1428.
14. Bishop J.F. Etoposide in the treatment of leukemia. Semin. Oncol. 19(Suppl 13):1992;33-38.
15. Hammond L.A., Eckardt J.R., Gamapaathi R., Burris H.A., Rodriguez G.A., Eckhardt S.G.et al. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin. Cancer Res. 4:1998;1459-1467.
16. Ando N., Eguch K., Shinkai I., Tamura T., Ohe Y., Yamamoto N.et al. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br. J. Cancer. 76:1997;1494-1499.
17. Herben V.M.M., Bokkel Huinink W.W., Dubbelman A.C., Mandjes I.A.M., Groot Y., Gortel-van Zomeran D.M.et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br. J. Cancer. 76:1997;1500-1508.
18. Eckhardt J.R., Burris H.A., Rodriguez G.A., Fields S.M., Rothenberg M.L., Moore T.D.et al. A phase I study of the topoisomerase I and II inhibitors topotecan and etoposide. Proc. ASCO. 12:1993;349a.
19. Boyum A. Separation of leukocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest. 21:1968;97.
20. Willson J., Gerson S., Haaga J., Berger S., Berger N. Biochemical modulation of drug resistance in colon cancers. Proc. AACR. 33:1992;236.
21. Duget M., Lavenot C., Harper F.et al. DNA topoisomerases from rat liver: physiologic variation. Nucleic Acid Res. 11:1983;1059-1075.
22. Champoux J.J., McConaughy B. Purification and characterization of the DNA untwisting enzyme for rat liver. Biochemistry. 15:1976;4638-4642.
23. Sabiers J.H., Berger N.A., Berger S.J., Haaga J.R., Hoppel C.L., Willson J.K.V. Phase I trial of topotecan administered as a 72 h infusion. Proc. AACR. 34:1993;426.
24. Rose P.G., Gordon N.H., Fusco N., Fluellen L., Rodriguea M., Ingalls S.T.et al. A phase II and pharmacokinetic study of weekly 72 h topotecan infusion in patients with platinum-resistant ovarian carcinoma. Gynecol. Oncol. 78:2000;228-234.
25. Stewart C.F., Baker S.D., Heideman R.L., Jones D., Crom W.R., Pratt C.B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol. 12:1994;1946-1954.
26. Beijnen J.H., Smith B.R., Keijer W.J., van Gijn R., Ven Bokkel Huinink W.W., Vlasveld L.T.et al. High performance liquid chromatographic analysis of the new anti-tumor drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal. 8:1990;789-794.
27. Vey N., Kantarjian H., Beran M., O'Brien S., Cortes J., Giles F.J.et al. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Blood. 92:1998;235a. [abstract 963].
28. Rowe J.M., Andersen J., Mazza J.J., Paietta E., Bennett J.M., Hayes A.et al. Phase III randomized placebo-controlled study on granulocyte-macrophase colony stimulating factor (GM-CSF) in adult patients (55-70 years) with acute myelogenous leukemia. (AML): a study of the Eastern Co-operative Oncology Group (ECOG). Blood. 86:1995;4570462.
29. Ohno R., Tonoga M., Kobayashi T., Kanamaru A., Shirakaw S., Masaoka T.et al. Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New Engl. J. Med. 323:1990;871.
30. Wall J.G., Burris H.A., Von Hoff D.D., Rodriguez G., Kneuper-Hall R., Shaffer D.et al. A phase I clinical and pharmacokinetic study of the topoisomerase inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs. 4:1992;337-345.
31. O'Dwyer PJ, LaCreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS. Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994;34:S46-52.
32. Haas N.B., LaCreta F.P., Walczak J., Hudes G.R., Brennan J.M., Ozols R.F.et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res. 54:1994;1220-1226.
33. Montazeri A., Boucard M., Lokiec F., Pinguet F., Culine S., Deport-Fety R.et al. Population pharmacokinetics of topotecan: intra-individual variability in total drug. Cancer Chemother. Pharmacol. 46:2000;375-381.
34. Van Warmerdam L.J.C., Creemers G.-J., Rodenhuis S., Roding H., deBoer-Dennert M., Schellens J.H.M.et al. Pharmacokinetics and pharmacodynamics of topotecan given on a daily times five schedule I phase II clinical trials using a limited sampling procedure. Cancer Chemother. Pharmacol. 38:1996;254-260.
35. Furman W.L., Baker S.D., Pratt C.B., Rivera G.K., Evans W.E., Stewart C.F. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J. Clin. Oncol. 14:1996;1504-1511.
36. Gallo J.M., Laub P.B., Rowinsky E.K., Grochow L.B., Baker S.D. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J. Clin. Oncol. 18:2000;2459-2467.
37. Perego P., Capranico G., Supino R.et al. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs. 5:1994;645-649.
38. Dubrez L., Goldwasser F., Genne O., Pommier S.E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia. 9:1995;1013-1024.
39. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., Kaufman S.H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:1993;271-291.
40. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 54:1994;1431.
41. Pommier Y., Leteurtre F., Fesen M.R.et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:1994;530.
42. Kapoor R., Slade D.L., Fujimori A.et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7:1995;83-95.
43. Fujimori A., Harker W.F., Kohlhagen G.et al. Mutation at the catalytic site of topoisomerase I in CEM/C2 a human leukemia cell line resistant to camptothecin. Cancer Res. 55:1995;1339-1346.
44. Kaufman S.H., Svingen P.A., Gore S.D.et al. Altered formation of topotecan stabilized topoisomerase I- DNA adducts in human leukemia cells. Blood. 89:1997;2098-2104.
45. Wang L.F., Ting C.Y., Lo C.K.et al. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res. 57:1977;1516-1522.
46. Beadler D.R., Chang J.Y., Zhou B.S.et al. Camptothecin resistance involving steps subsequent to the formation of protein linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res. 56:1996;345-353.
47. Saleem A., Ibrahim N., Patel M., Li X.G., Gupta E., Mendoza J.et al. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res. 57:1997;5100-5106.
48. Grabowski D., Ganapathi R. Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells. Ann. NY Acad. Sci. 803:1996;306-307.
49. Nair J.S., Kancherla R., Seiter K., Traganos F., Tse-Dinh Y.C. Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia: correlation of clinical and cell culture studies. Ann. NY Acad. Sci. 922:2000;326-329.
50. Whitacre CM, Belfi CA, Berger SJ, Gosky DM, Garcia J, Bao C, Sramkoki M, Berger NA. Cell cycle dependent modulation of topo IIá levels by topotecan in vitro: Potential implications on combination therapy with topo I and II inhibitors. Proc. AACR, 1999;40:109 [abstract 723].
51. Estey E., Alakha R.C., Hittelman W.N.et al. Cell cycle stage dependent variations in drug induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry. 26:1987;4338-4344.
52. Del Bino G., Skierski J.S., Darzynkiewicz Z. Diverse effects of camptothecin an inhibitor of topoisomerase I on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res. 50:1990;5746-5750.
53. Stahl M., Kasinir-Bauer S., Harstrick A. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anticancer Drugs. 8:1997;671-676.
54. Kaufman S.H. Antagonism between camptothecin and topoisomerase II directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 51:1991;1129-1136.
55. Vey N., Keating M.J., Rios M.B., Estery E. Effect of CR on survival in patients with AML receiving first salvage therapy. Blood. 92:1998;235a.
56. Gore S.D., Rowinsky E.K., Miller C.B., Griffin C., Chen T.L., Borowitz M.et al. A phase II window study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin. Cancer Res. 4:1998;2677-2689.